Navigation Links
Predicine and Flagship Biosciences Partner to Support Global Biomarker Development
Date:9/22/2018

Predicine and Flagship Biosciences are excited to announce a strategic venture. The synergistic combination of Predicine’s GeneRADAR molecular insights platform with Flagship’s artificial intelligence-enabled cTA® digital pathology platform provides complimentary and comprehensive biomarker profiling to empower clinical trials in the immuno-oncology (IO) space.

IO therapies have changed the way we think about patient selection for precision medicine. It is increasingly evident that an understanding of both the content and context of biomarkers is required to make IO therapeutic decisions. The complexity of tumor/immune interactions creates an opportunity to leverage multiple diagnostic approaches for understanding patient-specific response to immuno-oncology therapies. Thus, a composite approach is required. Predicine and Flagship work together to provide an integrated molecular and contextual tissue biomarker solution to advance the objectives of their pharmaceutical partners. This agreement also represents an expansion of Flagship’s global footprint as it works seamlessly with Predicine’s CAP-accredited precision cancer testing laboratories in China.

“We are excited to partner with Flagship, an industry leader in digital pathology that shares our commitment to advance precision medicine through innovation. We believe this alliance will greatly benefit our biopharma clients and is a further step in Predicine's goal to provide a comprehensive blood- and tissue-based biomarker profiling in support of global clinical trials, especially in the immuno-oncology space,” said Dr. Shidong Jia, Founder and CEO of Predicine.

“The combination of molecular and contextual tissue biomarkers represented by this venture between Flagship and Predicine will help patients everywhere by further empowering personalized medicine for global clinical trials in immuno-oncology” says Trevor D. Johnson, Flagship Biosciences CEO. “Flagship is proud to partner with Predicine to bring multi-dimensional insights to support complex IO clinical decisions around the world.”

About Predicine
Predicine is a molecular insights company that is committed to developing the best-in-class precision diagnostics and precision medicine portfolio to address the unmet medical needs worldwide. Predicine has developed "GeneRADAR", the industry's first ctDNA+ctRNA combo liquid biopsy test, to provide a comprehensive understanding of the molecular alterations in cancer. Through its integrated one-stop biomarker service facilities in US (California) and China (Shanghai, Harbin), Predicine partners with leading biopharma companies and hospitals to support global clinical trials, early cancer screening, and targeted therapy. For more, please visit http://www.predicine.com and follow Predicine on Twitter @Predicine.

About Flagship Biosciences
Flagship Biosciences Inc. delivers comprehensive tissue profiling for predictive diagnostics in drug therapy using an Artificial Intelligence (AI) enabled computational tissue analysis (cTA®) pathology analytics platform. Our intuitive data reporting gives researchers, clinicians, and drug developers the actionable information needed to drive better clinical results for patients. For more information on how Flagship accelerates drug development, please visit http://www.flagshipbio.com and follow Flagship on Twitter @FlagshipBio.

Read the full story at https://www.prweb.com/releases/predicine_and_flagship_biosciences_partner_to_support_global_biomarker_development/prweb15773409.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology technology :

1. BioXcel Launches Its Flagship Product, PharmGPS™
2. Flagship Biosciences Introduces a New Technique for Measuring Fibrosis in Nonalcoholic Steatohepatitis
3. Flagship Biosciences Expands Digital Pathology with Pharmaceutical Biostatistics Services
4. Flagship Biosciences Announces Relocation and Expansion
5. Elsevier Selected to Publish American College of Chest Physicians Flagship Journal CHEST
6. Deep Knowledge Ventures Flagship Investment Insilico Medicine Finalist at GPU Tech Conference
7. VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product
8. ARCH Venture Partners, Flagship Ventures and MD Anderson Collaborate to Launch Codiak BioSciences
9. Flagship Creates Clinical Trials and Regulatory Affairs Group
10. Flagship Ventures Brian Fiske Named To Forbes 30 Under 30 List
11. Flagship Biosciences and Beaufort, LLC Partner to Provide Clinical Trial Services for the Pharmaceutical Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2020)... ... ... This new service offers clients a way to speak with Subject Matter Experts ... arises. Lachman’s OnCall SMEs have extensive knowledge of a wide range of scientific, technical, ... are available normal business hours Monday through Friday from 9:00 am – 5:00 pm ...
(Date:5/14/2020)... , ... May 13, 2020 , ... ... assays or phenotypic readouts, providing little or no information on the drug’s mechanism ... more comprehensive characterization of compounds by measuring the activity of molecular pathways. This ...
(Date:5/1/2020)... YORK (PRWEB) , ... April 30, 2020 , ... ... Awards were announced today, honoring the businesses, policies, projects, and concepts that are ... a revolutionary bioprinter for living cells, which has taken out the top prize ...
(Date:4/22/2020)... ... April 21, 2020 , ... Ripple Science today announced new ... teams are working remotely and have paused patient visits, forcing teams to do ... research during this uncertain time by giving research teams free access to Ripple ...
Breaking Biology Technology:
(Date:4/22/2020)... , ... April 21, 2020 , ... Worcester Polytechnic Institute ... help provide critical medical supplies to address the expected spike of COVID-19 cases. As ... initiative, WPI has arranged for 3D printers and other materials to be sent to ...
(Date:4/16/2020)... ... April 15, 2020 , ... RoosterBio Inc., a leading supplier ... announces that the Medical Technology Enterprise Consortium (MTEC) recognized a multi-institution team with ... March. The Regenerative Medicine (RegenMed) biomanufacturing collaboration had created a team initiative led ...
(Date:4/14/2020)... ... April 14, 2020 , ... LabRoots , the leading ... provide cutting-edge research and findings about the latest developments in genomics and personalized ... more than 25 educational, scientific discussions, including 3 keynote deliveries on emerging areas ...
Breaking Biology News(10 mins):